Relay Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 5, 2025
RLAY$20.39+9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| March 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $93,542 | $124,287 |
| Investments | 616,813 | 657,036 |
| Prepaid expenses | 21,952 | 17,348 |
| Other current assets | 7,352 | 10,533 |
| Total current assets | 739,659 | 809,204 |
| Property and equipment, net | 5,148 | 5,911 |
| Operating lease assets | 50,136 | 51,762 |
| Restricted cash | 2,119 | 2,119 |
| Intangible asset | 2,300 | 2,300 |
| Total assets | $799,362 | $871,296 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $8,450 | $14,097 |
| Accrued expenses | 20,990 | 21,236 |
| Operating lease liabilities | 5,930 | 5,727 |
| Deferred revenue | — | 7,679 |
| Other current liabilities | 1,682 | 1,990 |
| Total current liabilities | 37,052 | 50,729 |
| Operating lease liabilities, net of current portion | 41,229 | 42,775 |
| Total liabilities | 78,281 | 93,504 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Undesignated preferred stock, $0.001 par value, 10,000,000 shares authorized as of March 31, 2025 and December 31, 2024; no shares issued and outstanding as of March 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value; 300,000,000 shares authorized as of March 31, 2025, and December 31, 2024; 170,483,872 and 167,755,715 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 168 | 168 |
| Additional paid-in capital | 2,536,230 | 2,516,905 |
| Accumulated other comprehensive gain (loss) | 38 | (991) |
| Accumulated deficit | (1,815,355) | (1,738,290) |
| Total stockholders’ equity | 721,081 | 777,792 |
| Total liabilities and stockholders’ equity | $799,362 | $871,296 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.